Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAGUE-8: Clopidogrel Loading Dose Strategies for Ad-Hoc PCI
NCT00432120Phase 3Completed
- Sponsor
- Charles University
- Start
- Mar 2006
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of clopidogrel in ischemic heart disease (IHD) (2 arms), sponsored by Charles University. Primary endpoint: Composite of death, periprocedural myocardial infarction, stroke, transient ischemic attack, or re-intervention at 7 days. Started Mar 2006; status: completed.
02
Drugs
clopidogrel
03
Conditions
ischemic heart disease (IHD)
Beyond the preview
Go deeper on NCT00432120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00432120.